A systematic review of the genetic mechanisms of dolutegravir resistance
Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …
HIV treatment and prevention 2019: current standards of care
N Phanuphak, RM Gulick - Current Opinion in HIV and AIDS, 2020 - journals.lww.com
HIV treatment and prevention 2019: current standards of care : Current Opinion in HIV and
AIDS HIV treatment and prevention 2019: current standards of care : Current Opinion in HIV …
AIDS HIV treatment and prevention 2019: current standards of care : Current Opinion in HIV …
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for …
J Van Wyk, F Ajana, F Bisshop, S De Wit… - Clinical Infectious …, 2020 - academic.oup.com
Background The 2-drug regimen dolutegravir (DTG)+ lamivudine (3TC) is indicated for
treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present …
treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present …
Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: A …
A Abdullahi, IM Kida, UA Maina… - Journal of …, 2023 - academic.oup.com
Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
Y Wang, E De Clercq, G Li - Expert opinion on drug metabolism & …, 2019 - Taylor & Francis
Introduction: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …
Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells
C Chu, D Armenia, C Walworth… - Clinical Microbiology …, 2022 - Am Soc Microbiol
SUMMARY HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non …
R Landman, P de Truchis, L Assoumou, S Lambert… - The Lancet …, 2022 - thelancet.com
Background Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
[HTML][HTML] HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review
R Patel, L Evitt, I Mariolis, S Di Giambenedetto… - Infectious Diseases and …, 2021 - Springer
The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
[HTML][HTML] DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 …
C Hidalgo-Tenorio, LL Cortés, A Gutiérrez, J Santos… - Medicine, 2019 - journals.lww.com
Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with
experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The …
experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The …
[HTML][HTML] Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES …
Objectives The aim of this study was to assess the efficacy of dolutegravir plus lamivudine
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …